major depressive disorder
Conditions
Interventions
Omega-3 Polyunsaturated fatty acid
placebo
Sponsors
University of Occupational and Environmental Health
National Center of Neurology and Psychiatry University of Toyama Tohoku Medical Megabank Organization, Tohoku University Tohoku Fukushi University Hakatachikushiguchi cocoro clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The subject did not receive any antidepressant drugs(≥4 weeks at minimal effective dose) for major depression 2. Total HDRS-17 score ≥17 3. The major depressive episode is the focus of the treatment and the treating physician has judged escitalopram to be its appropriate 1st line drug 4. A native Japanese speaker 5. The participant is able to understand and sign written informed consent.
Exclusion criteria
Exclusion criteria: 1. History of schizophrenia, schizoaffective disorder or bipolar disorder (DSM-IV) as judged by treating physician. 2. Current dementia, borderline personality disorder, eating disorder or substance dependence (DSM-IV) as judged by treating physician. 3. Imminent high risk of suicide as judged by treating physician. 4. Use of antipsychotic drugs and antidepressant drugs within 1 week of the visit 5. Physical diseases which may contraindicate treatment with escitalopram. 6. Currently pregnant or breast-feeding women 7. Regular consumption of polyunsaturated fatty acid supplements within the last 3 months 8. A habit of eating fish >= 4 times per week, to ensure comparability to patients studied in Western countries.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Raing Scale for Depression[Time frame: 12 weeks] | — |
Secondary
| Measure | Time frame |
|---|---|
| MADRS SDS BDI QIDS-J CGI-S RS-14 Serum BDNF, proBDNF, MMP-9, fatty acid level Plasma IL-6 | — |
Countries
Japan
Contacts
Public ContactWakako Nakano
University of Occupational and Environmental Health Department of Psychiatry
Outcome results
None listed